Intravenous immunoglobulin treatment of four patients with juvenile polyarticular arthritis associated with persistent parvovirus B19 infection and antiphospholipid antibodies

Table 2 Laboratory and clinical parameters of the patients during IVIG therapy

The patients were examined before and after the first treatment cycle (day 1, samples 1; day 5, samples 2), before and after the second treatment cycle (day 1, samples 3; day 5, samples 4), and 1 month (samples 5) and 9 months (samples 6) after the end of the second cycle. In addition to laboratory parameters including the amplification of parvoviral DNA derived from serum or synovial fluid, antiphospholipid antibodies (IgG anti-PL: anti-CL, anti-cardiolipin; anti-PS, anti-phosphatidylserine; anti-β₂GPI, anti-β₂-glycoprotein I; -, no reaction; +, positive, ++, strongly positive), doctors' and parents' global assessments of overall disease activity were recorded on a visual analogue scale (VAS) ranging from 0 (healthy) to 10 (severely affected). CK, creatine kinase; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; Hb, haemoglobin; IVIG, high-dose intravenous immunoglobulin; na, not available; nd, not determined; RBC, red blood cells; SF, synovial fluid; WBC, white blood cells.

ISSN: 1478-6362